ArticleJournal for immunotherapy of cancer2025

Response to: Correspondence on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer-a real-world, retrospective bicenter cohort study' by Wang.

Michiel M Smeenk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.